Project title: Estrogen Signaling in Low-Grade Serous Carcinoma (LGSOC) Research Institute: MD Anderson Cancer Center Lead Researcher: Dr KK Wong PhD, …
Impact of aromatase inhibitor therapy on women with gynaecological cancers
The University of Michigan (U-M) recently investigated the impact of aromatase inhibitor therapy on women with gynaecological cancers. Sharon Ritchie …
Verastem Oncology investigates new LGSOC treatment
Biopharmaceutical company Verastem Oncology has announced a new Phase 2 clinical trial for low-grade serous cancer (LGSOC). The trial will …
Cancer, Covid and Christmas
A Year of Change By Diane Evans-Wood Last year I wrote a blog about how to get through Christmas whilst …
Dana-Farber/Harvard Cancer Center awarded National Cancer Institute grant to study new combination therapy in LGSC
Low-grade serous carcinoma (LGSC) is often resistant to platinum based chemotherapy and new treatment strategies are needed. Dana-Farber/Havard Cancer Center …
Lili’s podcast for Ovarian Cancer Awareness Month
September is Ovarian Cancer Awareness Month. At just 28 years old Lili received the shock diagnosis of stage 4 low-grade …
Low-grade serous cancer research at MD Anderson Cancer Center
In July 2019 Cure Our Ovarian Cancer had the pleasure of speaking with world expert – Dr David Gershenson from …
Coping with cancer at Christmas
It’s November and already that time of year again when the Christmas adverts appear on TV and the shops are …
Binimetinib in low-grade serous carcinoma
A phase II study of Selumetinib, an oral small-molecule inhibitor of MEK1/2, has shown promising results in patients with recurrent …
Giving CuresDay on Giving Tuesday
Cure Our Ovarian Cancer is Celebrating GivingTuesday with #GivingCuresDay joining millions around the world participating in the global generosity movement, …